Pirfenidone Panel Highlights Difficulty Of Selecting Primary Endpoint In IPF

Though InterMune's pirfenidone still has the challenge of getting FDA approval based on mixed Phase III data using a not-yet validated primary endpoint, other drugs for idiopathic pulmonary fibrosis may face a clearer path to approvals following the Pulmonary-Allergy Drugs Advisory Committee March 9 review